Results 51 to 60 of about 1,470 (198)

Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience [PDF]

Background: We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the UK.
Ambrose, Philip, Burke, Georgina, Dionisio, Joana Moniz, Farrugia, Maria Elena, Garcia-Reitboeck, Pablo, Hewamadduma, Channa, Hill, Marguerite, Howard, Robin S, Jacob, Saiju, Kullmann, Dimitri, Leite, Maria Isabel, Miller, James, Norwood, Fiona, Pinto, Ashwin, Pritchard, Jane, Riswick, Thomas, Sathasivam, Sivakumar, Spillane, Jennifer, Thambirajah, Narmathey, Viegas, Stuart   +19 more
core   +5 more sources

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation

Frontiers in Neurology
BackgroundThe prevalence of patients positive for muscle-specific kinase antibody (hereafter, MuSK-Ab) accounts for 5–8% of all myasthenia gravis (MG) cases.
Fangyi Shi, Fangyi Shi, Fangyi Shi, Jiaxin Chen, Jiaxin Chen, Jiaxin Chen, Li Feng, Li Feng, Li Feng, Rong Lai, Rong Lai, Rong Lai, Hongyan Zhou, Hongyan Zhou, Hongyan Zhou, Xunsha Sun, Xunsha Sun, Xunsha Sun, Cunzhou Shen, Cunzhou Shen, Cunzhou Shen, Jiezhen Feng, Jiezhen Feng, Jiezhen Feng, Huiyu Feng, Huiyu Feng, Huiyu Feng, Haiyan Wang, Haiyan Wang, Haiyan Wang   +29 more
doaj   +1 more source

Usage of Newer Immunotherapies in Myasthenic Crisis – A Review of the Literature [PDF]

non
Dang, Johnny, Li, Yuebing, Uysal, Sanem
core   +2 more sources

Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler, Simon Lüdtke, Lena Dietze, Marie Schiffmann, Dominik Straube, Jan Ehrchen   +5 more
wiley   +1 more source

Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report

BMC Neurology
Background Generalized myasthenia gravis (gMG) can be managed with acetylcholinesterase inhibitors (AChEis; e.g., pyridostigmine), corticosteroids, other immunosuppressive drugs (e.g., tacrolimus), and their combinations. Intravenous immunoglobulin (IVIg)
Hiroya Ohara, Naoya Kikutsuji, Naohiko Iguchi, Masako Kinoshita   +3 more
doaj   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source

Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control

Biomedicines
Introduction: Myasthenia gravis (MG), an immune disorder affecting nerve-muscle transmission, often necessitates tailored therapies to alleviate longitudinal symptom fluctuations.
Shingo Konno, Takafumi Uchi, Hideo Kihara, Hideki Sugimoto   +3 more
doaj   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase

Frontiers in Immunology
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are autoimmune antibody-mediated diseases.
Weifan Yin, Weifan Yin, Shige Wang, Wei Lu, Wei Lu, Tianjiao Duan, Tianjiao Duan   +6 more
doaj   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source